Elsevier,
Additive Manufacturing Materials and Technologies, 3D Printing in Biotechnology, Elsevier, 2024, Pages 181-190
This chapter aligns with SDG Goal 3: Good Health and Well Being by discussing the environmental, economic, and social sustainability potential of 3D printing in biotechnology to provide a comprehensive understanding of this novel technology.
This study supports SDG 3 by examining the incidence of stroke among people with disabilities, a group who are more likely to have risk factors for stroke. The incidence was found to be almost 2.5 times higher than in non-disabled people, and occuring 20 years earlier. Public health measures are urgently needed to address this problem.
This paper probed the potential of using vegetation cover as an ecological barometer to gauge the level of environmental damage and restoration in mining areas.
Elsevier,
Artificial Intelligence in Clinical Practice, How AI Technologies Impact Medical Research and Clinics
2024, Pages 395-399
To harness the power and promise of AI in global health, adequate investment must be made in communication, computer systems, and supporting personnel to collect, curate, and manage the data necessary to enable benefits and minimize harm from the use of AI-related tools. In developed countries, this has either occurred or is underway. Developing countries run the risk of widening the digital divide if this does not occur. This chapter supports SDG3.
This research studied different heating systems in China and Europe. The sensitivity analysis found that electrifying heating systems with heat pumps can reduce household heating costs and mitigate European cities’ dependence on natural gas, providing policy recommendations on future building cost-effective retrofits and heating electrification in Europe.
This Article supports Sustainable Development Goal 3 by estimating the prevalence of dementia in people aged 60 years and older in Bangladesh, finding an overall prevalence of 8%, and identifying positive associations between dementia prevalence and female sex, advanced age, and lower education levels.
Elsevier,
Translational Sports Medicine
Handbook for Designing and Conducting Clinical and Translational Research
2023, Pages 513-518
This chapter focuses on n the population and environmental considerations that impact how patients receive care, identify health concerns, and empower them to take initiative in their own care with the health teams surrounding their care supporting SDG 3.
Public policy and linked social action must address the structural or intermediary social determinants of health. Though policy decisions or reform is one of the social action approaches, the programmatic, regulatory, and community development approaches need to be efficiently used. The COVID-19 pandemic expedited and facilitated collaboration with people outside the health sector. Such established and better-performing collaborations and social actions need continuation and expansion to other areas for better health and well-being. The national and subnational multisectoral action plan and its effective implementation can facilitate the “Health in All Policies” and address most of the social determinants of health.
To ensure sustainability, vertical or disease-specific programs or projects (government funded or external funded) should not develop standalone community participation interventions. They should be mandated to build on the existing social capital. The untied funds required for implementation of decentralized decision-making should be released in a timely manner without needless audit objections. Communities are not going to go anywhere. Hence, we need consistence in policy concerning community participation and patience from the administrators to implement community participation holistically with realistic sustainable short-term process indicators, while the focus is on medium- and long-term goals, including SDG3.
This Article supports Sustainable Development Goal 3 by advancing our understanding of the possible role of active immunotherapy against amyloid-β in individuals with mild Alzheimer's disease; the findings of this phase 2a study support the continued clinical development of UB-311 as an active immunotherapy for Alzheimer's disease.
